![HilleVax Inc](/common/images/company/N_HLVX.png)
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norov... HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Show more
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May...
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.54 | -10.5407255305 | 14.61 | 15.6 | 12.46 | 182297 | 14.29258544 | CS |
4 | -0.11 | -0.834597875569 | 13.18 | 15.6 | 10.935 | 221384 | 13.56854846 | CS |
12 | -3.48 | -21.0271903323 | 16.55 | 16.66 | 10.935 | 185014 | 13.5995012 | CS |
26 | -1.72 | -11.629479378 | 14.79 | 20.22 | 10.935 | 154092 | 14.66727679 | CS |
52 | -3.63 | -21.7365269461 | 16.7 | 20.22 | 9.94 | 121048 | 14.52230966 | CS |
156 | -5.69 | -30.3304904051 | 18.76 | 24.42 | 7.9 | 110432 | 14.84204304 | CS |
260 | -5.69 | -30.3304904051 | 18.76 | 24.42 | 7.9 | 110432 | 14.84204304 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.